A Study to Evaluate the Pharmacokinetics of HSK7653 in Subjects With Renal Impairment

Inclusion Criteria: Subjects with renal impairment(RI): 1. Voluntarily sign the informed consent form, understand the trial procedures, and be willing to comply with all trial procedures and restrictions; 2. 18 years to 79 years (inclusive), male and female; 3. Male subjects weight ≥50 kg and female subjects weight ≥45 kg. Body mass index (BMI) : 18-30 kg/m2 (inclusive) (BMI= weight (kg)/height2 (m\^2)); 4. Subjects with medically stable RI until study completion corresponding to the Classifications of Renal Function based on GFR: mild RI: 60≤GFR\<90 mL/min; moderate RI: 30≤GFR\<60 mL/min, severe RI:15≤GFR\<30 mL/min, kidney failure:GFR\<15 mL/min (not on hemodialysis); 5. Physical examination, vital sign measurements, 12-lead electrocardiogram (ECG), and clinical laboratory tests (hematology, serum chemistry, coagulation and urinalysis test) results were deemed appropriate by the investigator; 6. Not in use of any drug within 2 weeks prior to screening, except for the medication necessary for RI/ other comorbidities (last more than four weeks in good compliance); 7. Subjects (including partners) are willing to voluntarily use effective contraceptives from screening to at least 6 months after the last dose administration; Subjects with normal renal function : 1. Voluntarily sign the informed consent form, understand the trial procedures, and be willing to comply with all trial procedures and restrictions; 2. 18 years to 79 years (inclusive), male and female, age and sex must be matched with subjects with RI; 3. Male subjects weight ≥50 kg and female subjects weight ≥45 kg, weight must be matched with subjects with RI. Body mass index (BMI) : 18-30 kg/m\^2 (inclusive) (BMI= weight (kg)/height2 (m\^2)); 4. 90≤GFR\<130 mL/min; 5. Physical examination, vital sign measurements, 12-lead electrocardiogram (ECG), and clinical laboratory tests (hematology, serum chemistry, coagulation and urinalysis test) results were deemed appropriate by the investigator; 6. Not in use of any drug within 2 weeks prior to screening, except for the medication necessary for comorbidities (last more than four weeks in good compliance); 7. Subjects (including partners) are willing to voluntarily use effective contraceptives from screening to at least 6 months after the last dose administration； Exclusion Criteria: 1. Subjects who have a allergic history of DPP4 inhibitors or have a history of allergy to the test drug and the related compounds; 2. Have a history of severe and uncontrolled diseases, such as cardiovascular, respiratory, liver, gastrointestinal, endocrine, hematologic, mental/nervous systems diseases within one year prior to screening； 3. History or clinical evidence of acute or chronic pancreatitis, or clinically significant abnormalities in blood lipase and/or blood amylase results at screening; 4. Have conditions that may affect drug absorption, distribution, metabolism, or excretion (e.g., disease, drugs or surgery); 5. Use of any DPP-IV enzyme inhibitor within 2 weeks prior to the screening; 6. Experienced severe hypoglycemia within 3 months before screening; 7. Acute renal failure; 8. Smoking more than 5 cigarettes per day within 3 months prior to screening or smoking during the study； 9. Average alcohol intake is more than 14 unit per week (1unit=17.7 mL alcohol , 1 unit=357mL 5% alcohol beer, or 43mL 40% alcohol spirit, or 147mL 12% alcohol wine) within the 3 months prior to screening, or taking any alcohol during study or a positive ethanol breath test at screening; 10. Drug abuse history within 5 years prior to screening, or positive urine drug screen at screening； 11. History of high consumption of grapefruit juice, methylxanthine-rich food or beverage (such as coffee, tea, cola, chocolate, energy drinks) , consumption of grapefruit juice, methylxanthine-rich food within 48 hours before the administration ； 12. Participation in another clinical trial within 3 months before screening； 13. Blood donation (or blood loss) ≥400 mL, or receiving blood products to improve anemia within 3 months prior to the screening； 14. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) \> 2 × upper limit of normal, or bilirubin \> 1.5 × upper limit of normal； 15. Have a positive result for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, or anti-treponema pallidum specific antibody； 16. A pregnant/lactating woman, or has a positive pregnancy test at screening or during the trial； 17. Not suitable for this study as judged by the investigator.